| Mrs Wendy Vedrine, LMHC | |
|
126 Prospect St Ste 206, Pawtucket, RI 02860-4476 | |
| (401) 400-2135 | |
| Not Available |
| Full Name | Mrs Wendy Vedrine |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 126 Prospect St Ste 206, Pawtucket, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073038949 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | MHC01133 (Rhode Island) | Primary |
| Entity Name | Gateway Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821078932 PECOS PAC ID: 7719874908 Enrollment ID: O20040302001066 |
News Archive
iBio, Inc. today announced the grant of a commercial, royalty-bearing license to Fiocruz/Bio-Manguinhos of Brazil to develop, manufacture and sell certain vaccines based upon iBio's proprietary technology. Fiocruz/Bio-Manguinhos will invest more than $6 million to bring the first product - a new yellow fever vaccine - through Phase I clinical trials.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.
Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities and death, UC Davis researchers have found.
Facing the increasing prevalence of type 2 diabetes worldwide in the past few decades, one may ask what is wrong with humans. Geneticists tell us that the human genome has not changed markedly in such a short time.
Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Wendy Vedrine, LMHC 40 Dix Ave, Johnston, RI 02919-4851 Ph: (404) 903-5840 | Mrs Wendy Vedrine, LMHC 126 Prospect St Ste 206, Pawtucket, RI 02860-4476 Ph: (401) 400-2135 |
News Archive
iBio, Inc. today announced the grant of a commercial, royalty-bearing license to Fiocruz/Bio-Manguinhos of Brazil to develop, manufacture and sell certain vaccines based upon iBio's proprietary technology. Fiocruz/Bio-Manguinhos will invest more than $6 million to bring the first product - a new yellow fever vaccine - through Phase I clinical trials.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.
Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities and death, UC Davis researchers have found.
Facing the increasing prevalence of type 2 diabetes worldwide in the past few decades, one may ask what is wrong with humans. Geneticists tell us that the human genome has not changed markedly in such a short time.
Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).
› Verified 7 days ago
John Walker, M.A. Counselor Medicare: Not Enrolled in Medicare Practice Location: 160 Beechwood Ave, Pawtucket, RI 02860 Phone: 401-722-5573 | |
Trisha Johnson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 101 Bacon St, Pawtucket, RI 02860 Phone: 401-724-8400 Fax: 401-722-5280 | |
Susan Estrela, Counselor Medicare: Not Enrolled in Medicare Practice Location: 290 Kenyon Ave, Pawtucket, RI 02861 Phone: 401-632-6434 | |
Mr. James Gerard Gregory, LICSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 100 Lafayette St, Pawtucket, RI 02860 Phone: 401-771-7016 | |
Ms. Jennifer M Pelkey, MS Counselor Medicare: Not Enrolled in Medicare Practice Location: 249 Roosevelt Ave, Pawtucket, RI 02860 Phone: 401-724-8400 | |
Kelsey Francis, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 190 Cottage St Apt 1, Pawtucket, RI 02860 Phone: 603-819-9004 | |
John Echeverry, BACHELORS Counselor Medicare: Not Enrolled in Medicare Practice Location: 160 Beechwood Ave, Pawtucket, RI 02860 Phone: 401-722-5573 Fax: 401-724-9735 |